Belite Bio, Inc Share Price Börse Stuttgart
Equities
D01
US07782B1044
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
44 EUR | +1.38% | +0.46% | 0.00% |
14/05 | Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | 10M 9.2M 834M | Capitalization | 1.45B 1.33B 121B |
---|---|---|---|---|---|
Net income 2024 * | -31M -28.51M -2.59B | Net income 2025 * | -25M -23M -2.09B | EV / Sales 2024 * | - |
Net cash position 2024 * | 84.92M 78.11M 7.09B | Net cash position 2025 * | 49.8M 45.8M 4.16B | EV / Sales 2025 * | 140 x |
P/E ratio 2024 * |
-46.5
x | P/E ratio 2025 * |
-57.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
Latest transcript on Belite Bio, Inc
1 week | +0.46% | ||
Current month | +1.40% | ||
1 month | +15.73% |
Managers | Title | Age | Since |
---|---|---|---|
Yue Hsin Lin
CEO | Chief Executive Officer | 46 | 27/18/27 |
Hao Yuan Chuang
DFI | Director of Finance/CFO | 40 | 01/20/01 |
Nathan L. Mata
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 01/22/01 | |
Yi Ta Lue
BRD | Director/Board Member | 47 | 01/22/01 |
John Longo
BRD | Director/Board Member | 55 | 01/22/01 |
Date | Price | Change |
---|---|---|
06/24/06 | 44 | +1.38% |
05/24/05 | 43.4 | -1.81% |
04/24/04 | 44.2 | +0.45% |
03/24/03 | 44 | +2.80% |
31/24/31 | 42.8 | -3.60% |
Delayed Quote Börse Stuttgart, June 06, 2024 at 01:31 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.70% | 59.34B | |
+43.06% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- BLTE Stock
- D01 Stock